Haemostatic alterations induced by treatment with asparaginases and clinical consequences

Summary

The benefit of asparaginase for treating acute lymphoid leukaemia (ALL) has been well established. Native asparaginase derives from Escherichia coli (colaspase) or Erwinia chrysanthemi (crisantaspase); in a third preparation, colaspase is pegylated. Depletion of asparagine leads to decreased synthesis of procoagulant, anticoagulant, and fibrinolytic proteins, with resultant hypercoagulability and greater risk of venous thromboembolism (VTE). Colaspase and crisantaspase are not dose-equivalent, with crisantaspase displaying haemostatic toxicity only at dosages much higher and administered more frequently than those of colaspase. Cerebral venous thrombosis and pulmonary embolism are two life-endangering manifestations that occur during treatment with asparaginase particularly in children and in adults with ALL, respectively. Approximately one-third of VTEs are located in the upper extremities and are central venous line-related. Other risk factors are longer duration of asparaginase treatment and concomitant use of prednisone, anthracyclines, and oral contraceptives. The risk associated with inherited thrombophilia is uncertain but is clearly enhanced by other risk factors or by the use of prednisone. VTE prevention with fresh frozen plasma is not recommended; the efficacy of antithrombin (AT) concentrates has occasionally been reported, but these reports should be confirmed by proper studies, and AT should not be routinely employed. Therapeutic or prophylactic heparin doses are only partially effective, and direct thrombin or factor Xa inhibitors could play significant roles in the near future.

Keywords

Asparaginase - hypercoagulability - thrombosis - antithrombin concentrate - heparin

• References

• 1 Kidd J. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953; 98: 565-582.
• 2 Kidd J. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent; histological mechanism of the regression; tests for effects of guinea pig serum on lymphoma cells, in vitro discussion. J Exp Med 1953; 98: 583-606.
• 3 Broome J. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 1961; 191: 1114-1115.
• 4 Capizzi R. et al. L-Asparaginase: clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 1971; 74: 893-901.
• 5 Cooney D, Handschumacher R. L-asparaginase and L-asparagine metabolism. Ann Rev Pharmacol 1970; 10: 421-440.
• 6 Mashburn L, Wriston J. Tumour inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964; 105: 450-452.
• 7 Roberts J. et al. The antitumour activity of Escherichia coli L-asparaginase. Cancer Res 1966; 26: 2213-2217.
• 8 Campbell H. et al. Two L-asparaginases from E. coli B, their separation, purification and antitumour activity. Biochem Genet 1967; 06: 721-730.
• 9 Ho D. et al. Clinical pharmacologic studies of L-asparaginase. Clin Pharmacol Ther 1970; 11: 408-417.
• 10 Broome JD. L-Asparaginase: discovery and development as a tumour-inhibitory agent. Cancer Treat Rep 1981; 65 (Suppl. 04) 111-114.
• 11 Ollenschlager G. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 1988; 18: 512-516.
• 12 Avramis VI. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002; 99: 1986-1994.
• 13 Dinndorf PA. et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12: 991-998.
• 14 Appel IM. et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008; 22: 1665-1679.
• 15 Van Den Berg H. Asparaginase revisited. Leuk Lymphoma 2011; 52: 168-178.
• 16 Vieira Pinheiro JP. et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2, 500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006; 46: 18-25.
• 17 Asselin BL. et al. In vitro killing of acute lymphoblastic leukemia cells by L-as-paraginase. Cancer Res 1989; 49: 4363-4368.
• 18 Grigoryan RS. et al. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 2004; 18: 107-112.
• 19 Cory JG, Cory AH. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo 2006; 20: 587-590.
• 20 Ueno T. et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-as-paraginase. Leukemia 1997; 11: 1858-1861.
• 21 Pieters R. et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117: 238-249.
• 22 Rizzari C. et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013; 25 (Suppl. 01) S1-9.
• 23 Kurtzberg JA. Asparaginase. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, Gansler TS. eds. Holland-Frei Cancer Medicine. 5th edition.. Hamilton; BC Decker: 2000. . Chapter 51; pp. 699-705.
• 24 Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 02: 214-221.
• 25 Graham M. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003; 55: 1293-1302.
• 26 Oettgen HF. et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253-278.
• 27 Whitecar Jr JP. et al. Effect of L-asparaginase on carbohydrate metabolism. Metabolism 1970; 19: 581-586.
• 28 Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin during L-asparaginase therapy. N Engl J Med 1979; 301: 252-253.
• 29 Shapiro R. et al. L-asparaginase-induced hypocomplementemia in acute lymp-hocytic leukemia (ALL) of childhood. Am J Pediatr Hematol Oncol 1979; 01: 5-7.
• 30 Haskell CM. et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281: 1028-1034.
• 31 Deutsch E. et al. Blood coagulation changes under L-asparaginase therapy. Recent Results Cancer Res 1970; 33: 331-341.
• 32 Heene DL, Löffler H. The hemostatic defect induced by treatment with as-paraginase in leukemia. Recent Results Cancer Res 1970; 33: 342-343.
• 33 Ramsay NK. et al. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer 1977; 40: 1398-1401.
• 34 Sills RH. et al. L-Asparaginase-induced coagulopathy during therapy of acute lymphocytic leukemia. Med Pediatr Oncol 1978; 04: 311-313.
• 35 Anderson N. et al. L-asparaginase effect on antithrombin-III levels. Med Pediatr Oncol 1979; 07: 335-340.
• 36 Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-as-paraginase therapy. Med Pediatr Oncol 1980; 08: 7-14.
• 37 Pitney WR. et al. Antithrombin III deficiency during asparaginase therapy. Lancet 1980; 01: 493-494.
• 38 Vellenga E. et al. Antithrombin III deficiency during asparaginase therapy. Lancet 1980; 01: 649-650.
• 39 Conard J. et al. L-asparaginase, antithrombin III, and thrombosis. Lancet 1980; 01: 1091.
• 40 Priest JR. et al. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 1982; 100: 990-995.
• 41 Barbui T. et al. Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy. Acta Haematol 1983; 69: 188-191.
• 42 Bauer KA. et al. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res 1983; 29: 437-442.
• 43 Barbui T. et al. L-asparaginase lowers protein C antigen. Thromb Haemost 1984; 52: 216.
• 44 Reitz M. et al. Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment according to Protocol I of the Cooperative Leukaemia Study COALL-80. Klin Wochenschr 1984; 62: 1165-1169.
• 45 Vellenga E. et al. The influence of L-asparaginase therapy on the fibrinolytic system. Br J Haematol 1984; 57: 247-254.
• 46 Conard J. et al. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol 1985; 59: 725-727.
• 47 Kucuk O. et al. Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 1985; 55: 702-706.
• 48 Pui CH. et al. Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol 1985; 03: 1266-1272.
• 49 Vellenga E. et al. Thrombotic complications during L-asparaginase related to protein C deficiency?. Thromb Haemost 1985; 53: 443.
• 50 Bezeaud A. et al. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pedi-atr 1986; 108: 698-701.
• 51 Cappellato MG. et al. Clotting complications of L-asparaginase therapy in children with ALL. Blut 1986; 52: 377-378.
• 52 Marra R. et al. Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase. Acta Haematol 1986; 75: 96-99.
• 53 Miniero R. et al. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Am J Pediatr Hematol Oncol 1986; 08: 116-120.
• 54 Pui CH. et al. Vitamin K-dependent coagulation proteins in asparaginase-in-duced thrombosis. J Pediatr 1986; 109: 908-909.
• 55 Pui CH. et al. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol 1986; 64: 283-290.
• 56 Vicarioto M. et al. Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients. Folia Haematol Int Mag Klin Morphol Blutforsch 1986; 113: 663-669.
• 57 Homans AC. et al. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 1987; 05: 811-817.
• 58 Miniero R. et al. L-asparaginase-induced coagulopathy in children with acute lymphoblastic leukaemia. Drugs Exp Clin Res 1987; 13: 377-379.
• 59 Ollenschläger G. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 1988; 18: 512-516.
• 60 Saito M. et al. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol 1989; 32: 20-23.
• 61 Rodeghiero F. et al. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb Res 1990; 57: 31-38.
• 62 Semeraro N. et al. Unbalanced coagulation-fibrinolysis potential during L-as-paraginase therapy in children with acute lymphoblastic leukaemia. Thromb Haemost 1990; 64: 38-40.
• 63 Vigano’D’Angelo S. et al. L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent car-boxylation. Thromb Res 1990; 59: 985-994.
• 64 Sarris AH. et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79: 1305-1310.
• 65 Castaman G, Rodeghiero F. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. Haematologica 1993; 78 (Suppl. 02) (06) 57-60.
• 66 De Stefano V. et al. Hypercoagulability during induction therapy of acute lym-phoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto. Blood 1993; 81: 2468-2469.
• 67 Leone G. et al. Evidence of a hypercoagulable state in patients with acute lym-phoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost 1993; 69: 12-15.
• 68 Andrew M. et al. Acquired antithrombin III deficiency secondary to asparagi-nase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibri-nolysis 1994; 05 (Suppl. 01) S24-36.
• 69 Mazzucconi MG. et al. Antithrombin III infusion suppresses the hypercoagu-lable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis 1994; 05: 23-28.
• 70 Mitchell LG. et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol 1994; 16: 120-126.
• 71 Mitchell L. et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L‘Asparagi-nase-induced antithrombin III deficiency. Blood 1994; 83: 386-391.
• 72 Risseeuw-Appel IM. et al. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol 1994; 23: 335-343.
• 73 Nowak-Göttl U. et al. Asparaginase decreases clotting factors in vitro: a possible pitfall?. Int J Clin Lab Res 1995; 25: 146-148.
• 74 Nowak-Göttl U. et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996; 81: 127-131.
• 75 Nowak-Göttl U. et al. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different as-paraginase preparations. Eur J Pediatr 1997; 156: 848-850.
• 76 Kirschke R. et al. Coagulation and fibrinolysis in children with acute lymphob-lastic leukaemia treated according to the COALL-05-92-protocol. Klin Padiatr 1998; 210: 285-290.
• 77 Mall V. et al. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999; 211: 205-210.
• 78 Oner AF. et al. Changes of hemostatic factors in children with acute lymphob-lastic leukemia receiving combined chemotherapy including high dose methyl-prednisolone and L-asparaginase. Leuk Lymphoma 1999; 33: 361-364.
• 79 Albertsen BK. et al. Comparison of intramuscular therapy with Erwinia as-paraginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001; 115: 983-990.
• 80 Nowak-Göttl U. et al. Thromboembolic events in children with acute lymphob-lastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101: 2529-2533.
• 81 Appel IM. et al. L-Asparaginase and the effect of age on coagulation and fibri-nolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008; 100: 330-337.
• 82 Schneider P. et al. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol 2010; 148: 582-592.
• 83 Bettigole RE. et al. Hypofibrinogenemia due to L-asparaginase: studies of fibri-nogen survival using autologous 131-I-fibrinogen. Blood 1970; 35: 195-200.
• 84 Arens A. et al. Isolation and properties of L-asparaginases from Escherichia coli. Hoppe Seylers Z Physiol Chem 1970; 351: 197-212.
• 85 Boos J. et al. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 1995; 13: 2474-2475.
• 86 Ohnuma T. et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1979; 30: 2297-2305.
• 87 Wriston JC, Yellin TO. L-asparaginase: a review. Advanced Enzymol Relat Areas Mol Biol 1973; 39: 185-248.
• 88 Boos J. et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A: 1544-1550.
• 89 Boos J. Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Ther 1997; 35: 96-98.
• 90 Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003; 111: 199-212.
• 91 Sutor AH. et al. Gerinnungsveränderungen bei Behandlung mit den Protokollen ALL-BMF-90 und NHL-BMF-90. Klin Padiatr 1992; 204: 264-273.
• 92 Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78: 1637-1651.
• 93 Truelove E. et al. The coagulopathy and thrombotic risk associated with L-as-paraginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 2013; 27: 553-559.
• 94 Roemisch J. et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670.
• 95 Dahlbäck B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005; 579: 3310-3316.
• 96 Martinelli I. et al. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11: 140-156.
• 97 Kessel D, Bosmann HB. Effects of L-asparaginase on protein and glycoprotein synthesis. FEBS Lett 1970; 10: 85-88.
• 98 Hernández-Espinosa D. et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006; 169: 142-153.
• 99 Hernández-Espinosa D. et al. Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-as-paraginase treatment. J Thromb Haemost 2009; 07: 1128-1133.
• 100 Jaime-Perez JC, Gomez-Almaguer D. Platelet aggregation is stimulated by L-asparaginase in children with acute lymphoblastic leukemia and normal individuals. Haematologica 2002; 87: 891-892.
• 101 Pui CH. et al. Sequential changes in platelet function and coagulation in leu-kemic children treated with L-asparaginase, prednisone, and vincristine. J Clin Oncol 1983; 01: 380-385.
• 102 Shapiro RS. et al. Selective deficiency in collagen-induced platelet aggregation during L-asparaginase therapy. Am J Pediatr Hematol Oncol 1980; 02: 207-212.
• 103 Appel IM. et al. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. Blood Coagul Fibrinolysis 2006; 17: 139-146.
• 104 Gugliotta L. et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol 1990; 74: 465-470.
• 105 Pogliani EM. et al. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrom-botic state induced by therapy. Acta Haematol 1995; 93: 5-8.
• 106 Nowak-Göttl U. et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35-38.
• 107 Mitchell L. et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lym-phoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90: 235-244.
• 108 Lejhancova-Tousovska K. et al. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. Blood Coagul Fibrinolysis 2012; 23: 144-154.
• 109 Carlsson H. et al. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 1995; 55: 289-293.
• 110 Duval M. et al. Comparison of Escherichia coli asparaginase with Erwinia-as-paraginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of CancerChildren’s Leukemia Group phase 3 trial. Blood 2002; 99: 2734-2739.
• 111 Nocentini F. et al. Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data. Haema-tologica 1994; 79: 546-549.
• 112 Priest JR. et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980; 46: 1548-1554.
• 113 Cairo MS. et al. Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr 1980; 97: 829-833.
• 114 Urban C, Sager WD. Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia. Eur J Pediatr 1981; 137: 323-327.
• 115 Priest JR. et al. A syndrome of thrombosis and hemorrhage complicating L-as-paraginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984-989.
• 116 Caruso V. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216-2222.
• 117 Hunault-Berger M. et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lym-phoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008; 93: 1488-1494.
• 118 Gugliotta L. et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 1992; 49: 63-66.
• 119 Abbott LS. et al. The impact of prophylactic fresh-frozen plasma and cryopre-cipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009; 114: 5146-5151.
• 120 Santoro N. et al. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol Oncol 2013; 35: 348-355.
• 121 Mitchell LG. et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-516.
• 122 Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003; 111: 125-131.
• 123 Caruso V. et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007; 05: 621-623.
• 124 Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Hae-matol 2007; 138: 430-445.
• 125 Nowak-Göttl U. et al. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009; 22: 103-114.
• 126 Qureshi A. et al. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149: 410-413.
• 127 Grace RF. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Hae-matol 2011; 152: 452-459.
• 128 Lauw MN. et al. Venous thromboembolism in adults treated for acute lym-phoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost 2013; 109: 633-642.
• 129 Meister B. et al. Comparison of low-molecular-weight heparin and antithrom-bin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50: 298-303.
• 130 Ranta S. et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2013; 24: 749-756.
• 131 Nowak-Göttl U. et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595-1599.
• 132 Mauz-Körholz C. et al. Prothrombotic risk factors in children with acute lym-phoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000; 83: 840-843.
• 133 Nowak-Göttl U. et al. Thrombotic events revisited in children with acute lym-phoblastic leukemia: impact of concomitant Escherichia coli asparaginase/ prednisone administration. Thromb Res 2001; 103: 165-172.
• 134 Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 03: 19-25.
• 135 Halton JM. et al. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 1994; 47: 157-161.
• 136 Nowak-Göttl U. et al. Inefficacy of fresh frozen plasma in the treatment of L-as-paraginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995; 80: 451-453.
• 137 Steiner M. et al. Fresh froze plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy. Leukemia 2008; 22: 1290.
• 138 Mattioli Belmonte M. et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica 1991; 76: 209-14.
• 139 Matsuzaki A. et al. Antithrombin supplementation III in childhood acute lym-phoblastic leukemia treated with L-asparaginase. Pediatr Hematol Oncol 2002; 19: 601-603.
• 140 Hongo T. et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002; 44: 293-299.
• 141 Elliott MA. et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004; 45: 1545-1549.
• 142 Bucciarelli P. et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012; 10: 1783-1791.
• 143 Elhasid R. et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibri-nolysis 2001; 12: 367-370.
• 144 Harlev D. et al. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 2010; 126: 93-97.
• 145 Mitchell L. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115: 4999-5004.
• 146 Giordano P. et al. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the “Coagulation Defects” AIEOP Working Group. Recent Pat Cardiovasc Drug Discov 2007; 02: 53-62.
• 147 Bajzar L. et al. Thrombosis in children with malignancy. Curr Opin Pediatr 2006; 18: 1-9.
• 148 van der Hulle T. et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12: 1116-1120.
• 149 Kuhle S. et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparagi-nase: an in vitro study. Br J Haematol 2006; 134: 526-531.
• 150 Fukuda T. et al. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and hepa-rin. Thromb Res 2013; 131: 540-546.